CARD8

Across TCGA pan-cancer cohorts, CARD8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CARD8 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CARD8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CARD8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CARD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.383	1.000	<.001	17	view →
LUAD	DFS	Tertile	II,III,IV	0.888	0.334	.012	12	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	7	view →
GBM	DFS	Tertile	All	0.266	0.439	.014	7	view →
CCRCC	OS	Quartile	All	1.000	0.616	.030	5	view →
LSCC	DFS	Quartile	II,III,IV	0.504	0.870	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CARD8–PDAC (OS)

Open the PDAC breakdown →